<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02502344</url>
  </required_header>
  <id_info>
    <org_study_id>12015C1023</org_study_id>
    <nct_id>NCT02502344</nct_id>
  </id_info>
  <brief_title>Effect of Medical Interventions in Insulin Resistance on Prevalence of Abnormal Glucose Tolerance</brief_title>
  <acronym>MIIIROPOAGT</acronym>
  <official_title>The Research About the Influence of Medical Interventions in the Period of Insulin Resistance on Prevalence of Abnormal Glucose Tolerance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Tsinghua Chang Gung Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Tsinghua Chang Gung Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research would take medical interventions in subjects of insulin resistance without
      abnormal glucose tolerance, to see if there were different prevalence of abnormal glucose
      tolerance in different groups.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The situation of type 2 DM prevention in China is serious. The commonly accepted natural
      course of type 2 DM is as follows: obesity, insulin resistance(hyperinsulemia), abnormal
      glucose tolerance, DM and complications of DM; correspondently, the function status of
      pancreas islet β cells are: normal, compensatory, decompensatory, impaired and failure. Post
      researches have proved that using medical interventions after the period of insulin
      resistance when the function status of β cells were compensatory, the course could not be
      reversed. There were few clinical researches about effects of medical interventions in the
      period of insulin resistance . This research would take medical interventions in subjects of
      insulin resistance without abnormal glucose tolerance, to see if there were different
      prevalence of abnormal glucose tolerance in different groups.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2015</start_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>prevalence of abnormal glucose intolerance</measure>
    <time_frame>two years after the subject joins the research</time_frame>
    <description>OGTT test will be took in these subjects to find out if their glucose tolerance was abnormal</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>medical intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects in this group will accept healthy lifestyle changes such as food control and intensive exercise for 3 months first. Then their insulin resistance will be evaluated again . If their insulin resistance didn't improve, then they will take metformin 0.5g qd to reduce insulin resistance. If their insulin resistance improved, they will continued healthy lifestyle changes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>clinical observeral group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>subjects in this group will not accept medical interventions</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>healthy lifestyle</intervention_name>
    <description>food control and intensive exercise to lose weight</description>
    <arm_group_label>medical intervention group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>use metformin to reduce insulin resistance</description>
    <arm_group_label>medical intervention group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI &gt; 28kg/m2

          -  diagnosis of insulin resistance

        Exclusion Criteria:

          -  abnormal glucose tolerance

          -  function impairment of heart, liver or kidney
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jian Z Xiao, Doctor</last_name>
    <role>Study Director</role>
    <affiliation>Beijing Tsinghua Changgung Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zi Q Zeng, Doctor</last_name>
    <phone>0086-010-56118899</phone>
    <phone_ext>18101127014</phone_ext>
    <email>zzq@btch.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jian Z Xiao, Doctor</last_name>
    <phone>0086-010-56118899</phone>
    <phone_ext>13683685711</phone_ext>
    <email>xiaojzh858@sina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>BEI JING Tsinghua Changguang Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>102218</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>jian Z xiao, doctor</last_name>
      <phone>0086-010-56118899</phone>
      <phone_ext>13683685711</phone_ext>
      <email>xiaojzh858@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Ferrannini E, Mari A. β-Cell function in type 2 diabetes. Metabolism. 2014 Oct;63(10):1217-27. doi: 10.1016/j.metabol.2014.05.012. Epub 2014 Jun 11. Review.</citation>
    <PMID>25070616</PMID>
  </reference>
  <reference>
    <citation>Weir GC, Bonner-Weir S. Five stages of evolving beta-cell dysfunction during progression to diabetes. Diabetes. 2004 Dec;53 Suppl 3:S16-21. Review.</citation>
    <PMID>15561905</PMID>
  </reference>
  <reference>
    <citation>Samuel VT, Shulman GI. Mechanisms for insulin resistance: common threads and missing links. Cell. 2012 Mar 2;148(5):852-71. doi: 10.1016/j.cell.2012.02.017. Review.</citation>
    <PMID>22385956</PMID>
  </reference>
  <reference>
    <citation>Li G, Zhang P, Wang J, Gregg EW, Yang W, Gong Q, Li H, Li H, Jiang Y, An Y, Shuai Y, Zhang B, Zhang J, Thompson TJ, Gerzoff RB, Roglic G, Hu Y, Bennett PH. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet. 2008 May 24;371(9626):1783-9. doi: 10.1016/S0140-6736(08)60766-7.</citation>
    <PMID>18502303</PMID>
  </reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 15, 2015</study_first_submitted>
  <study_first_submitted_qc>July 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2015</study_first_posted>
  <last_update_submitted>July 19, 2016</last_update_submitted>
  <last_update_submitted_qc>July 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>insulin resistance</keyword>
  <keyword>abnormal glucose tolerance</keyword>
  <keyword>DM prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

